Glycated haemoglobin (HbA1c) is a measure of mean blood glucose levels over time. It is not a good indicator of day-today diabetes control and may not reveal variability in blood glucose. Continuous glucose monitoring (CGM) enables the real-time monitoring of glycaemic variability, potentially addressing issues such as episodic hypoglycaemia, hyperglycaemia, and the risk of complications associated with significant glycaemic excursions.
Given the quantity of data produced by CGM, there is a need for standardised analysis to enable patterns of blood glucose variation to be revealed. This need has been addressed by the development of specific software – the Ambulatory Glucose Profile (AGP) – which combines inputs from multiple days of CGM data and collates them into a single 24-hour period, making glycaemic patterns more recognisable. Clinical utility of AGP Main clinical situations where…
